| |
Nano Group |
Ferro Group |
Stenting Control |
ANOVA, p value |
| Number of enrolled patients, no. |
60 |
60 |
60 |
NA |
| Event-free survival (all cause), no. (%) |
55 (91.7%) |
49 (81.7%) |
48 (80.0%) |
0.031*
0.068 |
| Target lesion cardiac death, no. (%) |
0 (0%) |
0 (0%) |
1 (1.7%) |
> 0.05 |
| Target vessel cardiac death, no (%) |
0 (0%) |
2 (3.3%) |
1 (1.7%) |
0.091 |
Non-cardiac death, no. (%):
• Stroke
• Trauma
• Cancer
• Others |
5 (8.3%)
2 (3.3%)
2 (3.3%)
1 (1.7%)
0 (0%) |
9 (15.0%)
3 (5.0%)
4 (6.7%)
1 (1.7%)
1 (1.7%) |
10 (16.7%)
5 (8.3%)
4 (6.7%)
1 (1.7%)
0 (0%) |
0.032*, 0.064
> 0.05
> 0.05
>0.05
>0.05 |
| Target lesion myocardial infarction, no. (%) |
0 (0%) |
0 (0%) |
2 (3.3%) |
> 0.05 |
| Target vessel myocardial infarction, no. (%) |
3 (5.0%) |
6 (10.0%) |
4 (6.7%) |
0.029*, 0.059 |
| Target lesion revascularization (TLR), no. (%) |
2 (3.3%) |
2 (3.3%) |
4 (6.7%) |
0.058, 0.039# |
| Target vessel revascularization (TVR), no. (%) |
6 (10.0%) |
12 (20.0%) |
8 (13.3%) |
0.061, 0.043# |
Thrombosis of culprit artery, no. (%)
• ARC definite thrombosis |
0 (0%)
0 (0%) |
1 (1.7%)
1 (1.7%) |
4 (6.7%)
4 (6.7%) |
0.074, 0.028#
0.074, 0.028# |
Newcomers with diabetes mellitus, no. (%)
• Insulin-dependent |
9 (15.0%)
2 (3.3%) |
8 (13.3%)
1 (1.7%) |
5 (8.3%)
3 (5.0%) |
0.058
> 0.05 |
| Newcomers with SYNTAX score ≥23, no. (%) |
4 (6.7%) |
8 (10.0%) |
7 (11.7%) |
0.042*, 0.071 |
* - p-value for the difference between Nano and Ferro groups;